Nuveen LLC Takes $2.05 Million Position in Enliven Therapeutics, Inc. $ELVN

Key Points

• Nuveen LLC has acquired a stake in Enliven Therapeutics, Inc., purchasing 104,099 shares valued at approximately $2.05 million, representing about 0.21% of the company.
• Insider trading activity included CEO Samuel Kintz selling 12,500 shares, reducing his ownership stake by 1.31% following a sale valued at $281,500.
• Enliven Therapeutics recently reported a loss of ($0.49) earnings per share for the last quarter, beating analysts' expectations, and has an average target price of $41.20 from research analysts.

Nuveen LLC acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 104,099 shares of the company's stock, valued at approximately $2,049,000. Nuveen LLC owned about 0.21% of Enliven Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ELVN. Invesco Ltd. lifted its position in Enliven Therapeutics by 39.6% in the first quarter. Invesco Ltd. now owns 21,044 shares of the company's stock worth $414,000 after buying an additional 5,972 shares during the last quarter. BIT Capital GmbH purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth about $382,000. XTX Topco Ltd purchased a new stake in Enliven Therapeutics in the 1st quarter worth about $430,000. Bank of New York Mellon Corp lifted its stake in Enliven Therapeutics by 4.5% in the first quarter. Bank of New York Mellon Corp now owns 93,567 shares of the company's stock worth $1,841,000 after purchasing an additional 3,992 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Enliven Therapeutics by 4.9% during the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after buying an additional 2,466 shares during the period. Institutional investors own 95.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ELVN. HC Wainwright increased their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Jones Trading reduced their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Robert W. Baird boosted their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, June 16th. Finally, The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $41.20.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $20.63, for a total transaction of $67,047.50. Following the sale, the chief financial officer owned 23,000 shares of the company's stock, valued at approximately $474,490. The trade was a 12.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $18.24, for a total value of $121,606.08. Following the completion of the transaction, the chief operating officer directly owned 289,975 shares in the company, valued at approximately $5,289,144. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,234 shares of company stock valued at $2,186,231 in the last ninety days. 25.90% of the stock is currently owned by insiders.

Enliven Therapeutics Stock Down 4.5%

ELVN stock traded down $0.94 during trading on Thursday, hitting $20.01. 310,255 shares of the company's stock traded hands, compared to its average volume of 399,680. The firm has a market capitalization of $1.19 billion, a P/E ratio of -10.01 and a beta of 0.89. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The business has a fifty day simple moving average of $20.41 and a two-hundred day simple moving average of $19.77.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.